What Company Owns Mounjaro — and Why It Matters for Your Treatment

Eli Lilly owns Mounjaro: what that means in the UK supply chain

Eli Lilly and Company holds the UK marketing authorisation for Mounjaro. That is the legal instrument that allows a medicine to be manufactured, imported and sold in Britain, and it is granted and overseen by the MHRA. Lilly is the only entity permitted to manufacture tirzepatide pens bearing the Mounjaro name for the UK market. No other company can make or re-brand an identical product here.

In practice this means every genuine Mounjaro pen dispensed by a UK pharmacy (whether NHS or private) has come through Lilly's authorised distribution network. Pharmacies with direct supplier relationships with Eli Lilly UK can confirm the provenance of stock. It is one reason the company you choose to source Mounjaro from matters as much as the medicine itself.

Lilly's stewardship of the product also determines pricing. From 1 September 2025 the company raised UK list prices substantially, the highest-dose pen's list price moved from around £122 to around £330 per four-week pen, as widely reported in August 2025. Private providers pass these costs through in various ways, which is why prices vary considerably across the market.

Tirzepatide's development: Lilly's science in brief

A question our prescribers hear most weeks is whether Mounjaro is essentially the same as other weight-loss injections. It is not. Lilly developed tirzepatide as a dual agonist, activating both the GIP receptor and the GLP-1 receptor simultaneously. The GLP-1 pathway was already well-established through medicines like semaglutide; adding GIP activation appears to produce a meaningfully different appetite and metabolic response, as described in the NHS tirzepatide medicine page.

The clinical programme behind the UK licence is called SURMOUNT. SURMOUNT-1, published in the New England Journal of Medicine, randomised 2,539 adults with obesity and ran for 72 weeks; participants on the 15mg dose achieved an average body-weight reduction of around 20–21%. That evidence base is what Lilly submitted to the MHRA for approval and to NICE for appraisal. The resulting NICE recommendation, TA1026 published in December 2024, sets out which adults are recommended for tirzepatide through the NHS.

For adults pursuing treatment privately, those trial results are still the relevant benchmark. The medicine is identical; the route to it differs. You can read more about tirzepatide's mechanism and evidence base if you want the deeper science before deciding anything.

Manufacturer versus supplier: the distinction that protects you

Lilly makes Mounjaro. It does not sell directly to patients. Between manufacturer and patient sit authorised wholesalers, and then GPhC-registered pharmacies that hold a dispensing licence. Each link in that chain is regulated. When a pharmacy steps outside it (sourcing from unlicensed intermediaries, or when an online seller offers pens without conducting a clinical assessment) the chain of custody breaks, and with it any certainty about what is inside the pen.

The MHRA has been explicit on this point. In October 2025, enforcement teams raided the first known UK site producing counterfeit tirzepatide pens, seizing around 20 million doses of illegally traded weight-loss medicines with a street value of roughly £45 million. Fake pens can contain incorrect doses or entirely different substances. Knowing that Lilly is the only legitimate manufacturer gives you a reference point: if a pen cannot be traced back to Lilly's authorised UK supply chain, it should not be injected.

For anyone considering price as the main factor, it is worth pausing here. Price is a reasonable question; it is simply not the right primary test for a Prescription-Only Medicine. Provenance and clinical oversight are.

Choosing a regulated UK pharmacy: what ownership tells you about the process

Because Lilly holds the marketing authorisation, it also determines which wholesalers may handle Mounjaro stock. A pharmacy that can confirm an Eli Lilly supplier relationship is, by definition, operating within the authorised supply chain. That is one of several checks worth making when deciding which company to use for your Mounjaro prescription.

The others are straightforward: check the pharmacy on the GPhC register (GPhC premises registration for verification is public and searchable), confirm that a named prescriber reviews your consultation rather than an automated screening tool, and establish what aftercare is available if you have questions after your first pen arrives. These are the structural things that Lilly's ownership of Mounjaro cannot itself provide, they depend on the pharmacy and clinical service you choose.

If you are exploring your options, our free consultation is reviewed the same day by a GPhC-registered Independent Prescriber. There is no obligation, and no clinical assessment is ever replaced by software. For broader context on Mounjaro for weight management in the UK, including eligibility and how private access works, that page covers the full picture. You can also learn more about how nume operates as a GPhC-registered pharmacy, or read about our clinical team.